Leukocyte Adhesion Deficiency Management Market to Reach $11.28 Billion by 2029 at 7% CAGR

 Aimed at strategic decision-makers, this report explores current opportunities, emerging trends, and market dynamics shaping the leukocyte adhesion deficiency management sector.

 

 What Is The Projected Market Size & Growth Rate Of The Leukocyte Adhesion Deficiency Management Market?
 The leukocyte adhesion deficiency management market size has grown strongly in recent years. It will grow from $8.07 billion in 2024 to $8.59 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to increased awareness and education, genetic testing advancements, orphan drug designations, global health policies, patient advocacy groups, pediatric healthcare advancements.
 
 The leukocyte adhesion deficiency management market size is expected to see strong growth in the next few years. It will grow to $11.28 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to precision medicine approaches, emergence of novel therapeutics, expanded genetic testing accessibility, patient-centric drug development, advancements in immunomodulatory therapies. Major trends in the forecast period include stem cell transplantation innovations, integration of supportive therapies, telemedicine for remote consultations, collaboration and research networks, integration of biomarker technologies.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=13172&type=smp
 
 What Is The Crucial Factor Driving The Global Leukocyte Adhesion Deficiency Management Market?
 The rising prevalence of primary immunodeficiency is expected to propel the growth of the leukocyte adhesion deficiency management market going forward. Primary immunodeficiency (PID) is a group of inherited disorders that weaken the body’s immune system, making individuals more susceptible to infections and illnesses due to defects in their immune responses. Management of leukocyte adhesion deficiency benefits primary immunodeficiency by advancing the understanding of immune system disorders and potentially leading to improved diagnostic tools and therapies to help both conditions. For instance, in April 2023, according to the Peace Hospital, an India-based multi-specialty hospital, the data collected from World Primary Immunodeficiency (WPI) Awareness Week 2023 shows that primary immunodeficiency (PI) affects an estimated 60 lakh people globally, and 70% to 90% of people have undiagnosed primary immunodeficiency. Therefore, the rising prevalence of primary immunodeficiency will drive the growth of the leukocyte adhesion deficiency management market.
 
 Segment Covered In The Leukocyte Adhesion Deficiency Management Market Report
 The leukocyte adhesion deficiency managementmarket covered in this report is segmented — 
 
 1) By Treatment: Hematopoietic Stem Cell Transplantation; Recombinant Human Interferon-Gamma Treatment; Prophylactic Immunoglobulin Therapy; Antimicrobial Therapy; Prophylactic Therapy; Fucose Supplementation; Monoclonal Antibodies; Coagulation Factors
 2) By Diagnosis: Blood Test; Genetic Testing; Biopsy; Other Types
 3) By End-Users: Hospitals; Specialty Clinics; Other End-Users 
 
 Subsegments:
 1) By Hematopoietic Stem Cell Transplantation: Related Donor Transplant; Unrelated Donor Transplant 
 2) By Recombinant Human Interferon-Gamma Treatment: Standard Dosing; Customized Dosing 
 3) By Prophylactic Immunoglobulin Therapy: Intravenous Immunoglobulin (IVIG); Subcutaneous Immunoglobulin (SCIG) 
 4) By Antimicrobial Therapy: Antibiotics; Antifungal Treatments 
 5) By Prophylactic Therapy: Vaccination Strategies; Infection Prevention Protocols 
 6) By Fucose Supplementation: Oral Supplements; Intravenous Supplements 
 7) By Monoclonal Antibodies: Specific Target Monoclonal Antibodies; Combination Therapy Monoclonal Antibodies 
 8) By Coagulation Factors: Factor Replacement Therapies; Novel Coagulation Agents 
 
 
 Key Trends Driving Growth In The Leukocyte Adhesion Deficiency Management Market
 Major companies operating in the leukocyte adhesion deficiency management market are developing lentiviral vector-based gene therapy technology to improve targeted treatments and enhance patient outcomes. Lentiviral vector-based gene therapy offers a targeted approach in leukocyte adhesion deficiency management by delivering corrective genes directly into cells, potentially restoring immune function.For instance, in February 2024, Rocket Pharmaceuticals, a US-based biotechnology company, launched kresladi (marnetegragene autotemcel) for treating severe leukocyte adhesion deficiency-I (LAD-I). In a Phase 1/2 study, it achieved 100% survival at 12 months, significantly reducing infections and improving symptoms. Kresladi offers a groundbreaking option in the LAD management market, addressing critical unmet needs. 
 
 Key Player In The Leukocyte Adhesion Deficiency Management Market
 Major companies operating in the leukocyte adhesion deficiency management market report are F. Hoffmann-La Roche Ltd., Novartis AG, GlaxoSmithKline PLC, Gilead Sciences Inc., Teva Pharmaceuticals Industries Limited, CSL Behring LLC, Vertex Pharmaceuticals Inc., Grifols International S.A., Aurobindo Pharma Ltd., BioMarin Pharmaceutical Inc., Cadila Healthcare Ltd., Ipca Laboratories Ltd., Sana Biotechnology Inc., Rocket Pharmaceuticals Inc., PT Sanbe Farma, Magenta Therapeutics Inc., Avalo Therapeutics Inc., Aspen Neuroscience Inc., Sandoz International GmbH, Orpha Labs Inc., Swiss Pharm Holding AG, Rubius Therapeutics Inc., Enochian Biosciences Inc., Sigma-Aldrich LLC, Bluebird Bio Inc.
 
 View the full leukocyte adhesion deficiency management market report here:
 https://www.thebusinessresearchcompany.com/report/leukocyte-adhesion-deficiency-management-global-market-report
 
 Global Leukocyte Adhesion Deficiency Management Market — Regional Insights:
 North America was the largest region in the leukocyte adhesion deficiency management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukocyte adhesion deficiency management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company